Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 VALN | Healthcare | $5.66 | 2.72K | $538.58M | -2.85 | ― | Moderate Buy |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| VALN | Valneva | 5.66 | -3.39 | -37.46% |
| Name | Price | % Change | |
|---|---|---|---|
| VALN | $5.66 | -37.46% |
Valneva ( ($VALN) ) has provided an announcement. On November 9, 2026, Valneva announced positive results from two Phase 2 S4V2 trials in Kenyan infants and U.S. adults. S4V2 showed
Damien Choplain, an analyst from Stifel Nicolaus, reiterated the Buy rating on Valneva. The associated price target is €7.50. Damien Choplain’s rating is based on encouraging Phase II evidence for
Valneva ( ($VALN) ) has issued an announcement. Valneva SE is a specialty vaccine company that develops, manufactures and commercializes prophylactic vaccines for infectious diseases. It markets three proprietary travel
Valneva (VALN) announced that, following a further benefit-risk assessment of Ixchiq for travelers by the United Kingdom’s Commission on Human Medicines, or CHM, the UK marketing authorization for Ixchiq has
Pfizer (PFE) and Valneva (VALN) announced that the European Medicines Agency, or EMA, has validated the marketing authorization application, or MAA, for PF-07307405, the companies’ 6-valent outer surface protein A-based
The major averages were broadly lower near noon as investors continue to balance easing inflation pressures and strong corporate earnings against renewed geopolitical risks. The inflation backdrop remains supportive for
Shares in biotech Valneva ($VALN) soared over 20% in early trading today after it and partner Pfizer ($PFE) as it moved closer to bringing its Lyme disease vaccine to Europe.
TD Cowen initiated coverage of Valneva (VALN) with a Buy rating and $12 price target The company’s base vaccine business offers downside protection, while LB6V is a “de-risked” Lyme disease
Valneva Se (VALN) is scheduled to report 2nd quarter earnings on 08/13/2026. Regarding Q2 estimates, Wall Street analysts expect Valneva Se to post earnings of -$0.19 per share. Revenue expectations
The latest announcement is out from Valneva ( ($VALN) ). Valneva SE, a France-based specialty vaccine maker listed on Nasdaq and Euronext Paris, focuses on targeted prophylactic vaccines for infectious
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| VALN | Nov 24, 2026Before Open | $538.58M | $-0.20 | $43.67M | -0.01 | -2.85 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
